Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOEX.L Regulatory News (OEX)

  • There is currently no data for OEX

Update on Underwritten Rights Issue

3 Aug 2015 07:51

RNS Number : 8422U
Oilex Ltd
03 August 2015
 



ASX Announcement

 

3 August 2015

 

 

ASX: OEX

AIM: OEX

 

Update on Underwritten Rights Issue

 

Oilex Ltd (Oilex or the Company) is pleased to provide an update on the result of the previously announced Underwritten Rights Issue, and announces changes to the second tranche of the previously announced Placing.

 

As announced on 31 July 2015, 16,235,098 Rights Issue Shares have been taken up by shareholders, resulting in a shortfall in the Rights Issue of 153,241,412 shares. Under the terms of the underwriting agreement in respect of the Rights Issue, and as disclosed in the Company's announcement of 17 July 2015 (paragraph 5.7 of the Offer Booklet), as the share price of Oilex has, during the offer period, fallen below the A$0.041 Rights Issue offer price, a potential termination event has been triggered whereby the underwriter has the right to terminate the underwriting agreement.

 

In light of this development, the Company has taken steps to seek alternative participants for part of the Rights Issue shortfall. Accordingly, Zeta Resources Ltd (Zeta) has agreed to take up 62,011,067 shares by way of placement out of the Rights Issue shortfall at the Offer Price of A$0.041, for a total consideration of approximately A$2.55 million (£1.24 million, US$1.95 million) and will receive a fee of 6% that would otherwise have been paid to the underwriter. On this basis, the underwriter has agreed not to invoke its termination right under the underwriting agreement, and the underwriter (or its nominees) will take up the remaining Rights Issue shortfall.

 

As announced on 7 and 8 July 2015, Zeta's participation in the second tranche of the Placing will be settled in 2 tranches. As a result of Zeta's take up of Rights Issue shortfall shares as outlined above, and in order that it and its associates do not breach relevant Australian takeovers laws (under which, broadly, a person may not acquire shares if that would cause their and their associates' voting power to exceed 20%), Zeta has agreed that its second tranche investment will now proceed as follows (subject to approval of the resolutions proposed at the Company's General Meeting convened for 12 August 2015):

· 50,000,000 new ordinary shares will be placed with Zeta at a price of A$0.041 (2 pence) per share, to be settled immediately following the General Meeting;

· a further 124,019,608 (previously 225,490,196) new ordinary shares will be placed with Zeta at a price of A$0.0418 (2.04 pence) per share, to be settled by no later than 12 November 2015. These shares will be issued out of the authorisation to be sought at the General Meeting (covering 225,490,196 shares); and

· in lieu of the remaining shares originally envisaged to be issued to Zeta, (being 101,470,588 shares) the Company will issue A$4,243,500 (approximately £2.07 million) of 20 year, zero coupon unsecured convertible loan notes to Zeta, which will be convertible into shares at Zeta's option at any time, subject to compliance with Australian law, at a conversion price of A$0.0418 per share. The issue of these convertible notes will occur contemporaneously with the issue to Zeta of the 124,019,608 new ordinary shares referred to above. These convertible notes will be issued pursuant to the Company's placement capacity under Listing Rule 7.1 (as refreshed at the General Meeting). To the extent that the convertible notes are not converted, they will be redeemable on 30 June 2035 or such later date as agreed with Zeta. The Zeta Convertible Notes will have the right to participate in rights issues and other pro-rata issues on an "as converted" basis, subject to compliance with law.

 

 

Upon completion of the Rights Issue and Tranche 2 placing, Zeta and associates will hold approximately 275 million ordinary shares, representing approximately 19.6% of the Company's enlarged share capital (on an undiluted basis). Zeta will also hold A$4,243,500 of unsecured convertible notes, convertible into 101,470,588 ordinary shares.

 

The remaining portion of the second tranche of the Placing will proceed as previously announced and the Placing timetable remains unchanged. Given their relevance to the matters to be considered at the General Meeting, shareholders will be notified of the above changes by letter in the coming days.

 

 Managing Director of Oilex, Ron Miller, said;

"The financial support by Zeta not only in the second tranche, but now the Rights Issue shortfall is very pleasing and demonstrates their commitment to Oilex's business plan. This plan is focussed on production and cashflow from the recently independently assessed Reserves at our Cambay Field in India. We are delighted that the Rights Issue will successfully complete, leading to a General Meeting on 12 August 2015 where shareholders will have the opportunity to approve the second tranche of the Placing."

 

 

 

Yours faithfully,

  

Ron Miller

Managing Director

 

For further information, please contact the company or its advisors listed below:

 

PAC Partners Pty Ltd

Australian Broker

Andrew Shearer

Email: ashearer@pacpartners.com.au

Tel: +61 3 8633 9862

Australia

Westhouse Securities Limited

AIM Broker

Robert Finlay / Alastair Stratton

Email:  alastair.stratton@westhousesecurities.com

Tel: +44 20 7601 6100

UK

 

Strand Hanson Limited

Nominated Adviser

Rory Murphy /Ritchie Balmer

Email:  

oilex@strandhanson.co.uk

Tel: +44 20 7409 3494

UK

 

Vigo Communications

Public Relations UK

Patrick d'Ancona / Chris McMahon

Email:patrick.dancona@vigocomms.com

chris.mcmahon@vigocomms.com

Tel: +44 20 7016 9570

UK

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSRTAIVIIE
Date   Source Headline
14th May 20217:00 amRNSIssue of Securities and Appendix 2A
7th May 20217:00 amRNSNotice of General Meeting
6th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20219:55 amRNSChange of Interests of Substantial Holder
30th Apr 20217:36 amRNSMarch 2021 Quarterly Report
29th Apr 202111:06 amRNSIssue of Securities
23rd Apr 202110:24 amRNSIssue of Securities
23rd Apr 20217:00 amRNSInd Govt approval of Cambay PSC Work Prog/Budget
21st Apr 20211:43 pmRNSAcquisition Funding Arranged
13th Apr 20217:00 amRNSBhandut PSC PI Sale Finalisation
7th Apr 20215:51 pmRNSIssue of Securities
6th Apr 202111:00 amRNSPrice Monitoring Extension
6th Apr 20219:05 amRNSSecond Price Monitoring Extn
6th Apr 20219:00 amRNSPrice Monitoring Extension
1st Apr 20219:32 amRNSUpdate Regarding Cambay Settlement
17th Mar 20217:00 amRNSAppendix 2A
16th Mar 20217:00 amRNSCorrection: Equity Issue
15th Mar 20217:19 amRNSHalf Year Accounts
15th Mar 20217:00 amRNSSeries D Loan Restructure and Equity Issue
17th Feb 20217:00 amRNSAppendix 3Y P Schwarz
17th Feb 20217:00 amRNSAppendix 3Y P Haywood
15th Feb 20217:59 amRNSUpdate on proposal to acq interest in Cambay PSC
15th Feb 20217:46 amRNSTrading Halt Request
12th Feb 20218:15 amRNSIssue of Securities and Appendix 2A
1st Feb 20217:00 amRNSDecember 2020 Quarterly Report
24th Dec 20207:00 amRNSSeries C Loan Extension
17th Dec 202011:20 amRNSExecutive Directors Contract Extensions
17th Dec 202010:51 amRNSIssue of Securities
16th Dec 20207:00 amRNSResults of Annual General Meeting
14th Dec 20207:00 amRNSCompletion of East Irish Sea Transaction P2446
16th Nov 20207:00 amRNS2020 Notice of Annual General Meeting
6th Nov 20207:55 amRNSCorrection Waiver Granted
5th Nov 20207:30 amRNSWaiver Granted
2nd Nov 20207:00 amRNSAudited 2020 Annual Report - Financial Report
2nd Nov 20207:00 amRNSAudited 2020 Annual Report - Announcement
2nd Nov 20207:00 amRNSAudited 2020 Annual Report - Chairmans Review
2nd Nov 20207:00 amRNSAudited 2020 Annual Report - Directors Report
2nd Nov 20207:00 amRNSAudited 2020 Annual Report - Business Review
30th Oct 20209:54 amRNSSeptember 2020 Quarterly Report
30th Oct 20209:37 amRNSSeries C Loan Restructure
15th Oct 20208:54 amRNSArmour Completion and Update on Projects
1st Oct 20207:08 amRNSAppendix 4G
1st Oct 20207:00 amRNSCorporate Governance Statement 2020
1st Oct 20207:00 amRNSUnaudited 2020 Annual Report - Financial Report
1st Oct 20207:00 amRNSUnaudited 2020 Annual Report - Directors Report
1st Oct 20207:00 amRNSUnaudited Annual Report 2020 - Announcement
1st Oct 20207:00 amRNSUnaudited 2020 Annual Report - Business Review
1st Oct 20207:00 amRNSUnaudited 2020 Annual Report -Chairmans Review
14th Sep 202012:17 pmRNSArmour Share Purchase Agreement – Update
10th Aug 20207:00 amRNSIssue of Securities and Appendix 2A

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.